⌘K
Loading ticker…
Cytokinetics Inc. · Healthcare · Pharmaceutical Products
As of 2026-06-26, Cytokinetics Inc. (CYTK) has a 3-month relative strength percentile of 80 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 69. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 4.3%, relative volume 3.40×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
3m RS is 80, Market Stance is mixed at 47, A/D rating A
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
CYTK is in a stage 2 uptrend, week 2. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 13.5% / 27.5%.
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
Related searches
CYTK is held by 12 ETFs as of Mar 2026. Top owner: IJH at 0.25% weight, $267M notional. Top 3 carry $717M.
Top 10 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| IJHiShares Core S&P Mid-Cap ETF | 0.25% | $267M |
| VTIVanguard Total Stock Market ETF | 0.01% | $257M |
| IWMiShares Russell 2000 ETF | 0.27% | $193M |
| VBVanguard Small Cap ETF | 0.11% | $187M |
| VBKVanguard Small-Cap Growth ETF | 0.27% | $105M |
| VXFVanguard Extended Market ETF | 0.11% | $90M |
| XBIState Street SPDR S&P Biotech ETF | 1.18% | $88M |
| MDYState Street SPDR S&P MIDCAP 400 ETF Trust | 0.25% | $61M |
| ITOTiShares Core S&P Total U.S. Stock Market ETF | 0.01% | $10M |
| IWOiShares Russell 2000 Growth ETF | 0.06% | $7M |
Showing 10 of 12 ETF owners.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CYTK Jan avg: -2.28% median: -3.48% win: 25% σ: 5.78% n: 4 2022-04-12 → 2026-05-29 | CYTK Feb avg: -3.50% median: -4.26% win: 25% σ: 4.60% n: 4 2022-04-12 → 2026-05-29 | CYTK Mar avg: -7.12% median: -7.79% win: 25% σ: 10.89% n: 4 2022-04-12 → 2026-05-29 | CYTK Apr avg: -1.11% median: -2.92% win: 40% σ: 7.92% n: 5 2022-04-12 → 2026-05-29 | CYTK May avg: -5.53% median: 0.07% win: 60% σ: 19.01% n: 5 2022-04-12 → 2026-05-29 | CYTK Jun avg: 0.80% median: 2.49% win: 50% σ: 10.95% n: 4 2022-04-12 → 2026-05-29 (current) | CYTK Jul avg: 8.20% median: 8.33% win: 100% σ: 4.80% n: 4 2022-04-12 → 2026-05-29 | CYTK Aug avg: 5.12% median: 0.75% win: 50% σ: 14.11% n: 4 2022-04-12 → 2026-05-29 | CYTK Sep avg: 5.97% median: -8.01% win: 25% σ: 33.26% n: 4 2022-04-12 → 2026-05-29 | CYTK Oct avg: 5.18% median: 6.15% win: 50% σ: 13.96% n: 4 2022-04-12 → 2026-05-29 | CYTK Nov avg: 0.55% median: -0.48% win: 50% σ: 5.01% n: 4 2022-04-12 → 2026-05-29 | CYTK Dec avg: 35.29% median: 0.54% win: 50% σ: 76.43% n: 4 2022-04-12 → 2026-05-29 |